Medtronic (NYSE:MDT) Posts Earnings Results, Beats Estimates By $0.05 EPS

Medtronic (NYSE:MDT) announced its earnings results on Tuesday. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05, Zacks reports. The business had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%. Medtronic updated its FY 2026 guidance to 5.620-5.660 EPS.

Medtronic Trading Up 0.7%

NYSE:MDT opened at $96.52 on Tuesday. Medtronic has a 12 month low of $79.29 and a 12 month high of $99.37. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $123.80 billion, a price-to-earnings ratio of 26.59, a PEG ratio of 2.42 and a beta of 0.77. The firm has a fifty day simple moving average of $94.51 and a two-hundred day simple moving average of $90.52.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MDT. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research report on Wednesday, October 8th. Stifel Nicolaus lifted their target price on shares of Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Daiwa Capital Markets boosted their target price on shares of Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a report on Friday, September 12th. The Goldman Sachs Group cut their price target on shares of Medtronic from $82.00 to $81.00 and set a “sell” rating on the stock in a research report on Wednesday, October 1st. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $111.00 price target on shares of Medtronic in a report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $103.06.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William R. Jellison purchased 2,500 shares of the business’s stock in a transaction on Monday, August 25th. The stock was purchased at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the acquisition, the director owned 5,000 shares of the company’s stock, valued at approximately $461,850. This represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Medtronic

Several hedge funds and other institutional investors have recently modified their holdings of MDT. Florida Financial Advisors LLC raised its position in shares of Medtronic by 4.8% during the second quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock worth $234,000 after purchasing an additional 122 shares during the period. CYBER HORNET ETFs LLC increased its stake in Medtronic by 3.9% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,502 shares of the medical technology company’s stock valued at $334,000 after purchasing an additional 130 shares in the last quarter. Binnacle Investments Inc raised its holdings in Medtronic by 7.0% during the second quarter. Binnacle Investments Inc now owns 2,278 shares of the medical technology company’s stock worth $199,000 after buying an additional 150 shares during the last quarter. Sculati Wealth Management LLC lifted its stake in shares of Medtronic by 1.1% in the third quarter. Sculati Wealth Management LLC now owns 18,254 shares of the medical technology company’s stock valued at $1,739,000 after buying an additional 190 shares in the last quarter. Finally, Resurgent Financial Advisors LLC lifted its stake in shares of Medtronic by 4.2% in the third quarter. Resurgent Financial Advisors LLC now owns 5,494 shares of the medical technology company’s stock valued at $523,000 after buying an additional 220 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.